Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Multicenter, Randomized, Double-Blind, Placebo (Hepatitis E Vaccine) Controlled Study to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant (E.Coli) Human Papillomavirus Bivalent Vaccine in Healthy Women

Next Previous
X
Search
Trial Profile

A Phase III Multicenter, Randomized, Double-Blind, Placebo (Hepatitis E Vaccine) Controlled Study to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant (E.Coli) Human Papillomavirus Bivalent Vaccine in Healthy Women

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 18 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Human papillomavirus 16/18 vaccine recombinant bivalent Xiamen Innovax (Primary) ; Alum; Recombinant hepatitis E vaccine (Hecolin)
  • Indications Cervical cancer; Human papillomavirus infections
  • Focus Registrational; Therapeutic Use

    • Most Recent Events

    • 21 Feb 2020 Status changed from active, no longer recruiting to completed.
    • 31 Dec 2019 According to an Innovax Corporation media release, the China National Medical Products Administration (NMPA) today announced the approval of Cecolin (recombinant human papillomavirus bivalent (types 16, 18) vaccine).
    • 20 Dec 2019 Planned End Date changed from 28 Feb 2019 to 28 Dec 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top